Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets. In the historic dot.com year 2000, he trained as a CEFA analyst in Frankfurt and has since then accompanied over 20 IPOs in Germany.
Until 2018, he held various positions at banks as an asset manager, capital market and macro expert as well as fundamental equity analyst. He is passionate about the energy, commodity and technology markets as well as the tactical and strategic asset allocation of liquid investment products. As an expert speaker at investment committee meetings of funds as well as at customer events, he can still describe the course of the 1987 crash, one of the major buying opportunities of the last 33 years on the stock market.
Today, he knows that the profit in shares is not necessarily the result of buying cheaply, but above all of avoiding mistakes and recognizing in good time when markets are ready to let air out. After all, in addition to basic fundamental analysis, investing in stocks is above all a phenomenon of global liquidity and this must be monitored regularly.
Commented by André Will-Laudien
Commented by André Will-Laudien on November 13th, 2025 | 07:20 CET
Record stock market! And the momentum continues with Palantir, D-Wave, Gerresheimer, and NetraMark
Artificial intelligence (AI) is fundamentally changing drug development by analyzing vast amounts of data in record time and controlling clinical trials more precisely. Advanced systems identify promising drug candidates and predict therapeutic success with impressive accuracy. Companies such as NetraMark are already successfully using these technologies to accelerate development processes. At the same time, the well-known AI stars Palantir and D-Wave are driving the next wave of innovation as pacemakers in data analysis and quantum computing, recording extraordinary share price gains. The German Gerresheimer Group is also increasingly integrating AI-supported solutions into the manufacture of pharmaceutical packaging and medical technology. For investors, this represents a pool of opportunities, but the choice remains difficult!
Read
Commented by André Will-Laudien on November 12th, 2025 | 07:15 CET
More than 100%? Big Moves in gold and high-tech! Aixtron, Kobo Resources, Lanxess, and DroneShield
The next gold move is just around the corner. After the sharp rises in the third quarter, gold enthusiasts worldwide were already excited, and the USD 5,000 mark seemed a certainty. But things turned out differently: Unsurprisingly, the metal consolidated downward by a full USD 500 over the past three weeks. However, just below USD 3,800, the decline halted, and yesterday it was already climbing back to USD 4,100. The commodity market is still being driven by major uncertainty around the US shutdown and possible upcoming quantitative easing (QE) measures by the Fed. With the US debt ceiling again completely out of control at USD 38.5 trillion, a tangible solution is nowhere in sight. The sharp reduction in the current account deficit has brought little benefit to the US dollar, meaning that precious metals remain highly attractive against the backdrop of rising money supply and interest rates. Where should investors pay attention?
Read
Commented by André Will-Laudien on November 12th, 2025 | 07:05 CET
Time for savvy buyers! Should you get in now with thyssenkrupp, Plug Power, Nel ASA, Pure Hydrogen, or nucera?
Such volatility is rare on the stock markets. After months of upward movement, the potential for a correction has also been tested in recent days. Investors now need strong nerves and a clear focus on fundamentals - overvalued stocks can lose ground within a matter of days, even if the price build-up took months. Smart investors use so-called trailing stops, which automatically adjust upwards as valuations rise. In the best case, the automated exit is then triggered from above once the previously defined percentage loss threshold is reached. In the hydrogen sector, prices have moved erratically. Where should investors take action now?
Read
Commented by André Will-Laudien on November 11th, 2025 | 07:15 CET
Finding true value in the stock market! DroneShield, Palantir, and Globex Mining in Focus
Irrationality has become the new norm on the capital markets. While global economic growth has been stuttering for years, tech stocks on the NASDAQ are celebrating daily. Cautious voices are often ridiculed because, according to statistics, they are only proven right every 5 to 7 years. The penultimate sharp correction occurred 7 years ago in the fall of 2018, followed by two more, in 2020 and 2022, triggered by the pandemic and war. Since then, markets have been climbing almost relentlessly. The highly regarded DAX and NASDAQ indices have more than doubled since those corrections. Meanwhile, the Shiller P/E ratio has risen from 18 to 37 – incidentally, it peaked at 40 two weeks ago. Since then, volatility indicators have been reluctant to fall. The nervousness is palpable! We are using this most challenging of investment periods to reflect on what true value really means.
Read
Commented by André Will-Laudien on November 10th, 2025 | 07:30 CET
Mental mobilization! The EU places orders with Rheinmetall, Hensoldt, Antimony Resources, thyssenkrupp, and TKMS
With Russia stepping up attacks on Ukraine's energy infrastructure, parliamentarians in Brussels are realizing that only swift and decisive action can help close Europe's major security gaps. This means trillions in investments in defense technology and intensified Europe-wide cooperation. There is no room for hesitation or tactical maneuvering; funds must be saved elsewhere in order to protect the continent from potential aggression from the East. Time is short because by 2027, Europe aims to have a credible level of defense readiness. Investors can participate in this trend through carefully selected defense stocks. We cannot make the choice for you — but we do have a few ideas.
Read
Commented by André Will-Laudien on November 10th, 2025 | 07:00 CET
Takeover fever! BYD is amazed, Graphano celebrates, and Lyft buys FreeNow from Mercedes and BMW!
If the electric vehicle market wants to overtake combustion engines, further advances in battery technology are still needed. Consumers need to be convinced, which means that economic realities should be at the forefront of their purchasing decisions. Major innovations require high-performance materials, including graphite, which is a key component of modern lithium-ion batteries. Graphite contributes to a greater range, higher energy density, and improved safety. At the same time, innovative approaches to silicon anodes and novel cathode materials are ensuring more efficient and cost-effective production processes. With the steady expansion of charging infrastructure, range anxiety among consumers is diminishing, further boosting the adoption of e-mobility. This highly dynamic innovation environment thus opens up attractive prospects for both technology developers and investors, as the industry is changing rapidly.
Read
Commented by André Will-Laudien on November 7th, 2025 | 07:50 CET
Fact check: After the correction comes the next rally! Ups and downs for Almonty, Aixtron, and Deutsche Pfandbriefbank
Zigzag! Buy, sell, buy again! What wild volatility we are seeing on the trading board! Palantir delivers dream numbers, exceeding analysts' estimates by 10%, only to drop 20% after a brief rally. Traders have a saying for this: "Buy the rumor, sell the fact." Indeed, this kind of market behavior is often seen around earnings releases. In the case of Almonty, the stock surged an explosive 700% in just eight months, only to lose 40% in the subsequent correction. For flexible investors, it is worth taking a closer look and not losing sight of the fundamentals. Here are a few ideas for rocking the boat or tucking stocks away à la Kostolany!
Read
Commented by André Will-Laudien on November 6th, 2025 | 07:10 CET
Novo Nordisk calculating carefully, Evotec facing potential takeover? Clinical trial and up-listing at Vidac!
The stock market is showing some turbulence in the biotech sector. Unlike the big growth stocks on the NASDAQ, there is still urgent catching-up to do here. Some figures, such as those from Novo Nordisk and Evotec, still give reason for concern. The situation is quite different at Vidac Pharma, where an up-listing to the primary market is on the horizon and a clinical trial is about to begin! Plenty of material for investors' dreams to grow. We calculate where an investment is worthwhile!
Read
Commented by André Will-Laudien on November 5th, 2025 | 07:15 CET
Money or gold – Where can investors expect another 150% return? ESG-compliant with RE Royalties, Deutsche Bank, PayPal, or Fiserv?
Gold continues to fascinate as a scarce and value-preserving asset. However, its extraction often comes with significant environmental and social challenges, making the label "sustainable" difficult to apply. Money, on the other hand, especially in the form of cash or digital currency, is intangible and based on trust; in modern times, its sustainability is defined by its use in ESG-compliant investments. And these are diverse! With its "Green Deal," the EU is driving a comprehensive transformation and directing capital toward sustainable technologies and projects through support programs and ESG regulations. This is particularly relevant for institutional investors, who are increasingly required to consider climate risks and social responsibility. Much of this capital flows into green infrastructure and technological innovation. Private investors, meanwhile, have green investments on their radar, though the primary focus here remains on returns. Let's dive into the world of financiers.
Read
Commented by André Will-Laudien on November 4th, 2025 | 07:30 CET
Amazing! Rollercoaster ride with Beyond Meat, recovery at Novo Nordisk and Eli Lilly, big returns with PanGenomic Health
Volatility in the growth stock sector has caused quite a few swings in recent weeks. While Novo Nordisk and Eli Lilly are still struggling with margin declines from semaglutide injections, shares of the plant-based meat provider Beyond Meat have been bouncing around like a ball in orbit. After a rapid tenfold increase in October, November appears to be all about the reverse gear, with the stock currently down 80% from its peak. Those with strong nerves and a quick hand on the mouse are in luck. Things are calmer and steadier with PanGenomic Health. Here, the high levels since summer must first be digested before the next upward cycle can begin. We highlight a few opportunities.
Read